Advertisement

Topics

The EU HTA Harmonization Initiative: What is the Significance to Manufacturers of the New Directive?

09:31 EDT 24 Sep 2018 | Pharma-Voice

Comparative clinical benefit assessments are at the core of Health Technology Assessments (HTAs) in Europe. HTAs are a multi-disciplinary process considering input and evidence from medical, social, and economic sources. They are used to inform the design of health policies that allow the safe and effective use of new technologies within individual health systems and […]

The post The EU HTA Harmonization Initiative: What is the Significance to Manufacturers of the New Directive? appeared first on PharmaVOICE.

Original Article: The EU HTA Harmonization Initiative: What is the Significance to Manufacturers of the New Directive?

NEXT ARTICLE

More From BioPortfolio on "The EU HTA Harmonization Initiative: What is the Significance to Manufacturers of the New Directive?"

Advertisement
Quick Search
Advertisement
Advertisement